甲状腺癌组织中长链非编码RNA浆细胞瘤变体易位1和微小RNA-195-5p表达及临床意义

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (684 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the expression and clinical significance of long non-coding RNA (lncRNA) plasmacytoma variant translocation 1 (PVT1) and microRNA (miRNA)-195-5p in thyroid carcinoma tissue. Methods The expression of lncRNA PVT1 and miR-195-5p in 82 cases of thyroid cancer tissues, adjacent normal tissues and 82 cases of benign thyroid tumor tissues treated in Changzhou of Hospital Traditional Chinese Medicine from April 2017 to January 2020 were detected by fluorescence real-time quantitative PCR (qRT-PCR), the relationship between the two indexes and clinicopathological parameters of patients with thyroid cancer and the correlation between the two inedxes was analyzed. Results The relative expression level of lncRNA PVT1 in thyroid cancer tissues was higher than that in benign thyroid tumor tissues and paracancerous normal tissues, while the relative expression level of miR-195-5p was lower than that in benign thyroid tumor tissues and paracancerous normal tissues (all P ＜ 0.05). In thyroid cancer, the relative expression level of lncRNA PVT1 with lymph node metastasis and TNM stage Ⅲ-Ⅳ stage was higher than that without lymph node metastasis and Ⅰ-Ⅱ stage. The relative expression level of miR-195-5p in lymph node metastasis and TNM stage Ⅲ-Ⅳ stage was lower than that in the non-lymph node metastasis and Ⅰ-Ⅱ stage (all P ＜ 0.05).The expression of lncRNA PVT1 in thyroid cancer tissues was negatively correlated with the expression of miR-195-5p (r = -0.731, P < 0.01). Conclusion The increased lncRNA PVT1 and decreased miR-195-5p in thyroid carcinoma tissues are related to lymph node metastasis and TNM stage, which have potential application value for assessment of patients’ condition and determining therapeutic targets.

Key words： Thyroid carcinoma long non-coding RNA plasmacytoma variant translocation 1 Micro RNA-195-5p Correlation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Xiaoling1 SHAO Xin1 GUO Ling2 YANG Yali3

Cite this article:

LI Xiaoling1 SHAO Xin1 GUO Ling2 YANG Yali3. Expression and clinical significance of long non-coding RNA plasmacytoma variant translocation 1 and microRNA-195-5p in thyroid carcinoma tissue[J]. 中国医药导报, 2021, 18(19): 22-26.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I19/22

[1] 李斐，李舍予.全球甲状腺癌疾病负担[J].中国全科医学，2018，21（26）：3155-3159.
[2] Yoshida K，Toden S，Ravindranathan P，et al. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2，and the lncRNA PVT1 expression [J]. Carcinogenesis，2017，38（10）：1036-1046.
[3] Xu H，Gong J，Liu H. High expression of lncRNA PVT1 independently predicts poor overall survival in patients with primary uveal melanoma [J]. PLoS One，2017，12（12）：e0189675.
[4] Luo Q，Zhang Z，Dai Z，et al. Tumor-suppressive microRNA-195-5p regulates cell growth and inhibits cell cycle by targeting cyclin dependent kinase 8 in colon cancer [J]. Am J Transl Res，2016，8（5）：2088-2096.
[5] Xu H，Hu YW，Zhao JY，et al. MicroRNA-195-5p acts as an anti-oncogene by targeting PHF19 in hepatocellular carcinoma [J]. Oncol Rep，2015，34（1）：175-182.
[6] Bosman FT，Cameiro F，Hruban RH，et al. Worldhealth organization classification of tumours of the digestive system [M]. Lyon：IARC Press，2010.
[7] 马大坤，代文杰.分化型甲状腺癌侧颈淋巴结的规范性清扫[J].西安交通大学学报：医学版，2019，40（3）：442-444，479.
[8] 陈万青，郑荣寿，张思维，等.2012年中国恶性肿瘤发病和死亡分析[J].中国肿瘤，2016，25（1）：1-8.
[9] 秦嘉黎，石香玉，刘善廷.甲状腺癌病因学研究新进展[J].中华耳鼻咽喉头颈外科杂志，2020，55（7）：711-715.
[10] 龚化，周治军，卢童，等.长链非编码RNA NEAT1对肾癌细胞增殖和侵袭能力影响的机制研究[J].中国医师杂志，2019，21（3）：356-359，363.
[11] Wu Z，Li Y，Zhang G. Downregulation of microRNA-301a inhibited proliferation，migration and invasion of non-small cell lung cancer by directly targeting DLC1 [J]. Oncol Lett，2017，14（5）：6017-6023.
[12] 姜晓娟，江啸，王芙蓉，等.微小RNA-218表达在胃癌中的作用机制研究进展[J].中华实验外科杂志，2019， 36（6）：1154-1157.
[13] Wan L，Sun M，Liu GJ，et al. Long Noncoding RNA PVT1 Promotes Non-Small Cell Lung Cancer Cell Proliferation through Epigenetically Regulating LATS2 Expression [J]. Mol Cancer Ther，2016，15（5）：1082-1094.
[14] Huang T，Liu HW，Chen JQ，et al. The long noncoding RNA PVT1 functions as a competing endogenous RNA by sponging miR-186 in gastric cancer [J]. Biomed Pharmacother，2017，88（7）：302-308.
[15] Yang T，Zhou H，Liu PJ，et al. lncRNA PVT1 and its splicing variant function as competing endogenous RNA to regulate clear cell renal cell carcinoma progression [J]. Oncotarget，2017，8（49）：85353-85367.
[16] Li Z，Wang H，Wang Z，et al. miR-195 inhibits the proliferation of human cervical cancer cells by directly targeting cyclin D1 [J]. Tumour Biol，2016，37（5）：6457-6463.
[17] Chen S，Wang L，Yao X，et al. miR-195-5p is critical in REGγ-mediated regulation of wnt/β-catenin pathway in renal cell carcinoma [J]. Oncotarget，2017，8（38）：63986-64000.
[18] Zhang X，Xu J，Jiang T，et al. MicroRNA-195 suppresses colorectal cancer cells proliferation via targeting FGF2 and regulating Wnt/β-catenin pathway [J]. Am J Cancer Res，2016，6（11）：2631-2640.
[19] Jin J，Wang C，Ouyang Y，et al. Elevated miR-195-5p expression in deep vein thrombosis and mechanism of action in the regulation of vascular endothelial cell physiology [J]. Exp Ther Med，2019，18（6）：4617-4624.
[20] Yu W，Liang X，Li X，et al. MicroRNA-195：a review of its role in cancers[J]. Onco Targets Ther，2018，11（1）：7109-7123.
[21] 刘晓敏.MicroRNA-195-5p抑制宫颈癌细胞迁移、侵袭和上皮间质转化及其机制研究[D].沈阳：中国医科大学，2020.
[22] Shen CJ，Cheng YM，Wang CL. LncRNA PVT1 epigenetically silences miR-195 and modulates EMT and chemoresistance in cervical cancer cells [J]. J Drug Target，2017， 2（9）：1-19.
[23] Conte F，Fiscon G，Chiara M，et al. Role of the long non-coding RNA PVT1 in the dysregulation of the ceRNA-ceRNA network in human breast cancer [J]. PLoS One，2017，12（2）： e0171661.
[24] Zhang Y，Mo WJ，Wang X，et al. Microarray-based bioinformatics analysis of the prospective target gene network of key miRNAs influenced by long non?coding RNA PVT1 in HCC [J]. Oncol Rep，2018，40（1）：226-240.
[25] Landa I，Ganly I，Chan TA，et al. Frequent somatic TERT promoter mutations in thyroid cancer： higher prevalence in advanced forms of the disease [J]. J Clin Endocrinol Metab，2013，98（9）：1562-1566.